Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum.

Samuel Dunyo, Rosalynn Ord, Rachel Hallett, Musa Jawara, Gijs Walraven, Eduardo Mesa, Rosalind Coleman, Maimuna Sowe, Neal Alexander, Geoffrey A T Targett, Margaret Pinder, Colin J Sutherland
{"title":"Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum.","authors":"Samuel Dunyo, Rosalynn Ord, Rachel Hallett, Musa Jawara, Gijs Walraven, Eduardo Mesa, Rosalind Coleman, Maimuna Sowe, Neal Alexander, Geoffrey A T Targett, Margaret Pinder, Colin J Sutherland","doi":"10.1371/journal.pctr.0010014","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with resistance to CQ or SP.</p><p><strong>Design: </strong>We conducted a single-blind, randomised, controlled trial to compare the efficacy of CQ/SP to that of SP or CQ alone.</p><p><strong>Setting: </strong>The study took place in the town of Farafenni and surrounding villages in the Gambia.</p><p><strong>Participants: </strong>Participants were children aged 12 mo to 10 y presenting as outpatients with uncomplicated P. falciparum malaria.</p><p><strong>Interventions: </strong>500 children were randomised to receive CQ, SP, or CQ/SP as supervised treatment and actively followed over 28 d.</p><p><strong>Outcome measures: </strong>Primary outcome was parasitaemia at any time during follow-up. Secondary outcomes were PCR-confirmed recrudescent infections among treatment failures, and clinical failure requiring rescue medication by day 28. Pretreatment parasite isolates from 161 patients were tested for the presence of resistance-associated genetic markers.</p><p><strong>Results: </strong>The prevalence of parasitological failure by day 28 for the CQ group was 60.3%, compared to 17.6% for SP (odds ratio [OR], 0.106; 95% confidence interval [CI], 0.057-0.194; p < 0.001) and 13.9% for CQ/SP (OR versus CQ, 0.140; 95% CI, 0.078-0.250; p < 0.001). There was no difference between the SP and CQ/SP groups (OR, 1.324; 95% CI, 0.705-2.50). The projected prevalence of PCR-corrected treatment failure was 30.2, 6.06, and 3.94% in the CQ, SP, and CQ/SP groups, respectively. The pfdhfr-triple mutant and pfdhps-437G mutation were common, with prevalences of 67.4 and 51.2%, respectively. Pretreatment carriage of pfdhps-437G and of multidrug-resistant parasite genotypes was associated with treatment failure in the SP group, but not in the CQ or CQ/SP groups.</p><p><strong>Conclusions: </strong>The combination of CQ/SP was an efficacious treatment for uncomplicated malaria in Gambian children in this study, but the frequent occurrence of multidrug-resistant parasites suggests that this observed efficacy is not sustainable.</p>","PeriodicalId":87416,"journal":{"name":"PLoS clinical trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2006-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513406/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1371/journal.pctr.0010014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with resistance to CQ or SP.

Design: We conducted a single-blind, randomised, controlled trial to compare the efficacy of CQ/SP to that of SP or CQ alone.

Setting: The study took place in the town of Farafenni and surrounding villages in the Gambia.

Participants: Participants were children aged 12 mo to 10 y presenting as outpatients with uncomplicated P. falciparum malaria.

Interventions: 500 children were randomised to receive CQ, SP, or CQ/SP as supervised treatment and actively followed over 28 d.

Outcome measures: Primary outcome was parasitaemia at any time during follow-up. Secondary outcomes were PCR-confirmed recrudescent infections among treatment failures, and clinical failure requiring rescue medication by day 28. Pretreatment parasite isolates from 161 patients were tested for the presence of resistance-associated genetic markers.

Results: The prevalence of parasitological failure by day 28 for the CQ group was 60.3%, compared to 17.6% for SP (odds ratio [OR], 0.106; 95% confidence interval [CI], 0.057-0.194; p < 0.001) and 13.9% for CQ/SP (OR versus CQ, 0.140; 95% CI, 0.078-0.250; p < 0.001). There was no difference between the SP and CQ/SP groups (OR, 1.324; 95% CI, 0.705-2.50). The projected prevalence of PCR-corrected treatment failure was 30.2, 6.06, and 3.94% in the CQ, SP, and CQ/SP groups, respectively. The pfdhfr-triple mutant and pfdhps-437G mutation were common, with prevalences of 67.4 and 51.2%, respectively. Pretreatment carriage of pfdhps-437G and of multidrug-resistant parasite genotypes was associated with treatment failure in the SP group, but not in the CQ or CQ/SP groups.

Conclusions: The combination of CQ/SP was an efficacious treatment for uncomplicated malaria in Gambian children in this study, but the frequent occurrence of multidrug-resistant parasites suggests that this observed efficacy is not sustainable.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在冈比亚疟疾患儿中开展氯喹/磺胺乙胺嘧啶随机试验:对耐多药恶性疟原虫的影响。
目标:在冈比亚,氯喹(CQ)和磺胺乙胺嘧啶(SP)的组合疗法已取代CQ单一疗法,用于治疗由恶性疟原虫引起的疟疾。我们测定了CQ/SP联合疗法的疗效,以及携带与CQ或SP抗药性相关等位基因的寄生虫的流行率:我们进行了一项单盲、随机对照试验,比较CQ/SP与SP或单用CQ的疗效:研究地点:冈比亚法拉芬尼镇及周边村庄:干预措施:500 名儿童随机接受 CQ/SP 治疗:500 名儿童被随机分配接受 CQ、SP 或 CQ/SP 作为监督治疗,并接受 28 天的积极随访:主要结果:随访期间任何时间的寄生虫血症。次要结果是治疗失败者中经 PCR 证实的再发感染,以及在第 28 天前需要使用抢救药物的临床失败。对来自 161 名患者的治疗前寄生虫分离物进行了抗药性相关基因标记检测:第28天时,CQ组的寄生虫学治疗失败率为60.3%,而SP组为17.6%(几率比[OR]为0.106;95%置信区间[CI]为0.057-0.194;P < 0.001),CQ/SP组为13.9%(OR与CQ相比为0.140;95% CI为0.078-0.250;P < 0.001)。SP 组和 CQ/SP 组之间没有差异(OR,1.324;95% CI,0.705-2.50)。预计 PCR 校正治疗失败的发生率在 CQ、SP 和 CQ/SP 组分别为 30.2%、6.06% 和 3.94%。pfdhfr-三突变体和pfdhps-437G突变很常见,发生率分别为67.4%和51.2%。治疗前携带 pfdhps-437G 和耐多药寄生虫基因型与 SP 组的治疗失败有关,但与 CQ 或 CQ/SP 组无关:结论:在这项研究中,CQ/SP联合疗法对冈比亚儿童的无并发症疟疾治疗有效,但耐多药寄生虫的频繁出现表明,这种疗效并不持久。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. A cluster-randomised trial evaluating an intervention for patients with stress-related mental disorders and sick leave in primary care. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. The effect of acclydine in chronic fatigue syndrome: a randomized controlled trial. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1